iShares Genomics Immunology and Healthcare ETF
iShares Genomics Immunology and Healthcare ETF (IDNA) Stock Overview
Explore iShares Genomics Immunology and Healthcare ETF’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
103.1M
P/E Ratio
N/A
EPS (TTM)
$1.26
ROE
0.00%
IDNA Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of iShares Genomics Immunology and Healthcare ETF (IDNA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
Our forecasting models predict significant price movements, with a 12-month target of $24.68.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of N/A and a market capitalization of 103.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Company Profile
The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
DE
2019